Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

HIV Test Recommended When Specific Indicator Diseases Present

By LabMedica International staff writers
Posted on 21 Mar 2012
Heterosexuals are at particular risk of carrying the Human immunodeficiency virus (HIV) for so long that they remain undiagnosed until their immune system starts to fail and they become ill. More...


It has recently been revealed that a number of diseases, including herpes zoster and certain forms of cancer, should be on the list of indicators for having HIV, and thus serve to prompt health care professionals to suggest an HIV-test to their patients.

An international study under the leadership of the HIV in Europe initiative (Copenhagen, Denmark) and under the auspices of the University of Copenhagen (Denmark) will debate how to disseminate knowledge of the new HIV indicator diseases to non-HIV doctors and health care professionals across Europe. The HIV in Europe initiative took up this challenge in 2009 and started the study HIV Indicator Diseases Across Europe (HIDES), which investigated eight new diseases and how often they proved to be signs of an undiagnosed HIV infection among the 3,588 patients in the study.

The sooner HIV-infected individuals receive a diagnosis and start therapy, the greater are their chances of survival and their quality of life. Investigators have shown that therapy lowers the risk of passing the infection on to someone else. Half of all people living with HIV are diagnosed very late in the course of their chronic HIV infection. People infected through heterosexual transmission now comprise 42 % of these late presenters, as a study of 90,000 Europeans tested HIV positive since 2000 shows. The Joint United Nations Program on HIV and AIDS, known as UNAIDS, has estimated that 2.5 million Europeans carry an HIV infection, and as many as 900,000 of these, are still unaware of this. Inside the European Union, the numbers are 800,000 infected with 250,000 undiagnosed.

Jens Lundgren, MD, the chief physician and director of the Copenhagen HIV Program, said " We could see that if an adult had a sexually transmitted infection, malignant lymphoma, cervical or anal cancer/dysplasia, herpes zoster, hepatitis B or C, ongoing mononucleosis-like illness, inexplicable, persistent decline in the number of circulating white blood cells, or seborrheic dermatitis/exanthema, the risk of HIV infection was so high that it would be cost-effectiveness for society to routinely offer them a test". He added, "The incidence of HIV is greater for these eight indicator diseases and they should encourage health care professionals to offer the patient an HIV test. Draft guidelines on how to ensure this throughout Europe are one of the topics we need to debate and decide on, before they can be implemented." The new results and guidelines are to be debated at a major international HIV conference in Copenhagen, Denmark on March 19-20, 2012.

Related Links:
HIV in Europe
University of Copenhagen



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.